

Setting biometric assumptions in a post-COVID world

Ben Johnson, Rob Mellows, Craig Armstrong

Post-pandemic biometric assumption setting working party

What we'll cover today

- Working party objectives, scope and background
- Options for setting mortality assumptions
- Overview of risk drivers
- Practical application of driver-based approach



Working Party objectives

- Produce a reference paper for Chief Actuaries on setting biometric assumptions in a postpandemic era
- Bring together findings from existing research in one place
- Complementary to CMI Working Paper 177



Working Party scope

- Longevity and mortality IN SCOPE
- Morbidity NOT DIRECTLY IN SCOPE
- Lapse OUT OF SCOPE
- Best estimate assumptions for UK lives
- Principles not precise assumptions

** Paper release expected by end September **



Working Party – use-cases of paper

- 1. Sense check for existing risk driver approaches
- 2. Support construction of a risk driver approach
- 3. Example of simple risk driver comparison to core CMI model





Setting assumptions

Pre- and post-pandemic

Background: setting assumptions Pre-COVID-19

- Stable methodologies relying on adding most recent year of data
- Data sources for mortality base table and improvements:
 - Base tables -> portfolio of experience
 - Improvements -> population data e.g. CMI model
- The drivers of mortality improvements can be investigated to help answer questions:
 - Will historically important factors continue to be so in the future?
 - How will changing medical practices impact on mortality improvements?
 - How to adjust mortality improvements for socioeconomic group and level of underwriting?
- COVID-19 challenges the existing practice



Background: Post-2019 mortality data



- Cumulative standardised mortality rates relative to 2019
- Without COVID-19, you'd expect 2020, 21, 22 and 23 lines to track successively lower in the negative axis
- Cumulative standardised mortality to week 32 of 2023 is 5.0% above 2019



Source: CMI mortality monitor as at 22nd Aug 2023

Options for setting assumptions Post-COVID-19

- Material changes to the data:
 - -Mortality spikes in 2020 and 2021
 - -Excess deaths in 2022 and 2023
- What should we do with the data? Typical options used by firms fit under 3 options:
 - Option 1: Ignore or down-weight data impacted by COVID-19
 - **Option 2:** Adjust data impacted by COVID-19
 - **Option 3:** Carry out a bottom-up analysis of the risk drivers



Option 1 Ignore or down-weight data impacted by COVID-19





Option 1 Ignore or down-weight data impacted by COVID-19

Advantages	Disadvantages		
Simple to apply	Lost insights from ignored data		
Easy to rationalise for 2020 and 2021	Unclear what approach appropriate for 2022		

- Exclusion of 2020 & 2021 data continues to be reasonable
- Simple 2022 weighting approach may be appropriate for smaller books
- Note core parameterisation of CMI model with 25% weight to 2022 data



Option 2 Adjust data impacted by COVID-19



Institute and Faculty

of Actuaries

Option 2 Adjust data impacted by COVID-19

Advantages	Disadvantages
Significant mortality impacts still captured	Difficulty of identifying "COVID deaths"
Retain insights into other drivers	Inaccuracy of approximate adjustment methodology

- Treats direct COVID-19 deaths as entirely short-term and indirect excess deaths as permanent
- Crude approach but could be reasonable for very immature or less material portfolios



Option 3 Driver-based approach





Option 3 Driver-based approach

Advantages	Disadvantages		
Insights should lead to better-informed assumption	Resource intensive		
Can consider impacts over different time periods	Requires expert judgement		

- Comprehensive approach which requires investment of resources to identify and quantify mortality drivers
- A version of this approach may well be most appropriate for material books





Drivers of post-pandemic mortality

Driver-based approach

Why?

• Need to understand the drivers of heavy 2022/23 mortality to determine which simpler methods might be reasonable (e.g. weight on 2022 experience, CMI22 model)

How does this working paper help?

- Shortlist the potentially key drivers
- Categorise "probably high" v "probably low" materiality
- Help focus on high materiality ones
- Introductory analysis \rightarrow signpost important papers + suggestions for further analysis
- Considerations for projection

The WP has aimed to provide useful guidance but doesn't provide "the answer"



Shortlisted drivers





Institute and Faculty of Actuaries

Shortlisted drivers



Reduced Respiratory/Influenza Deaths

+14% +12% +10% +8% +6% +4% +2% 0% -2% 1 Jan 1 Feb 1 Mar 1 Apr 1 May 1 Jun 1 Jul 1 Aug 1 Sep 1 Oct 1 Nov 1 Dec 1 Jan ---- 2013 ---- 2014 ---- 2015 ---- 2016 ---- 2017 - 2021 - 2019 2018 - 2020 - 2022 - 2023

Interpreting 2022/23 – timing of deaths

Conclusion looking forward

- Short term: Likely stabilisation of influenza mortality at similar pre-pandemic levels, with some risk of increased severity in the short term.
- Medium/Long term: Potential for some reduction in mortality compared to the short term from mRNA technology developments.
- [Interaction with endemic COVID competing causes]





Deaths in England & Wales involving COVID-19

- Left: Deaths by year of registration and age-band.
- Right: Deaths involving COVID-19 expressed as a percentage of all other (non-COVID-19) deaths registered in the year and age-band.

Age-band	2020	2021	2022	2023 YTD	Age-band	2020	2021	2022	2023 YTD
0-24	54	120	88	20	0-24	1.1%	2.2%	1.6%	0.7%
25-49	1,445	2,452	740	158	25-49	6.7%	11.4%	3.4%	1.4%
50-74	18,940	22,163	7,094	2,144	50-74	13.1%	15.7%	4.9%	2.7%
75+	60,391	51,359	25,218	9,360	75+	16.7%	15.0%	6.8%	4.5%
Total	80,830	76,094	33,140	11,682	Total	15.2%	14.9%	6.1%	3.9%

• Source: figures are derived from ONS death registration data. 2023 YTD is to end-June.

Contribution to 2022 and 2023 excess deaths?

- Death certificates: deaths "due to" COVID are ca. 2/3 of deaths "involving" COVID in 2022 and 2023.
- Some over or under reporting possible
- Competing causes?





Conclusion looking forward

- Endemic: here to stay
- Short term: Likely stabilisation of mortality at similar levels to recent experience.
- Medium/Long term: Likely reduction in mortality compared to recent experience, due to a reduction in disease severity and improvements in treatment.



Adverse Health Implications of COVID-19 and Pandemic

Acute Post COVID-19 Sequelae

- Impact: Likely to have a material impact in the short term and a small impact in the medium/long term if the endemic steady-state of COVID infections is low.
- **Rationale:** Recent studies suggest mortality rates are significantly heightened in the 6-18 month period immediately following the acute phase of a COVID-19 infection:

nature medicine	6	ESC Gardiovascular Research (2023) 119, 1718–1727 of Cardiology https://doi.org/10.1093/cvr/coac195	medicine	ARTICLES https://doi.org/10.1038/s41591-022-01689-3
Acute and postacute sec with SARS-CoV-2 reinfec	puelae associated tion	Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality: a prospective cohort in UK Biobank	OPEN Long-term	Cardiovascular outcomes of COVID-19

- Hazard ratios of between 1.5 and 5.0 reported, so the effect is significant.
- These studies consider periods of up to 18 months and so it is not possible to say how long the heightened risk will last. Assuming some run-off with time since infection seems reasonable, but it remains possible that it persists to the longer term

of Actuaries

 Reasonable to assume that the severity of sequelae follow the severity of initial infection, so run-off with cohort also a reasonable assumption

Overall direct COVID view?

Explanation of 2022/2023 excess

More detailed exploration might separately consider:

Projection?





Probably lessening over time?





Complicated interaction between a number of issues







Emergency care waiting times

- Left: category 2 (emergency) average ambulance response times vs the target of 18 minutes since the start of 2019.
- Right: The percentage of A&E attendances resolved within 4 hours from arrival to admission, transfer, or discharge





Elective care waiting times

• Number of people on NHS waiting list for consultant-led elective care August 2007-Dec 2022

Number of people on NHS waiting lists for consultant-led elective care





Source: NHS England

Health Service Disruption

Quantification?

- A&E waiting times:
 - Research by Lane Clark & Peacock estimates that more than 400 additional deaths a week (between Sept 2022 to Feb 2023) could be due to long delays in accessing emergency care. Not all these deaths could be typically defined as excess deaths but could all be considered 'avoidable'
 - Example if ca. 200 deaths pw were excess then 10k p.a. = ca. 2% of annual E&W mortality.

• Elective care waiting times:

- Lancet Oncology 2020 paper modelled substantial increases in the number of avoidable cancer deaths in England from diagnostic delays \rightarrow 3-4k additional deaths within 5 years.
- 2020 collaboration between GAD, DHSC, ONS, Home Office estimated that delays to elective care could lead to around 12.5k excess deaths over a 5-year period.

CVD risk factor management:

 The British Heart Foundation 'Tipping Point' report estimates that the reduction in control of hypertension could lead to 11,190 additional heart attacks and 16,702 additional strokes over a three-year period.

Wait watchers







Slower to

emerge into

mortality

statistics?

Institute and Faculty of Actuaries

Health service impact in the medium/long-term?

- Granular modelling of different drivers (e.g. A&E waits v cancer waits) more difficult in the longer term.
- An alternative approach is to take a view on:

The likely trajectory for NHS spending in aggregate

Х

The "elasticity" of subsequent mortality with respect to health spending

less

Any allowance that you already have in your prepandemic best estimate

- What to assume for the relationship?
 - A range of views exist on the size and timing of this relationship
 - For example, analysis in the November 2020 IFOA longevity bulletin noted the results of a regression analysis that suggested each 1% additional funding received by the NHS might give rise to a 0.4% decrease in mortality rates, coming through over the subsequent 10 years





Institute and Faculty of Actuaries



Conclusion looking forward

- Short term: Excess mortality is likely to persist in the immediate future with the potential for it to increase as a result of delays to diagnoses/treatment and the challenges facing emergency and social care.
- Medium/Long term: Impact on mortality is dependent on the NHS hitting their targeted path to recovery.
- There are plans in place to fix the biggest issues facing the NHS, but it is a large and complex entity so the impact of any positive changes will likely only be felt over a long period rather than in the short-term.

Implicit assumptions from the pre-pandemic period likely to be important



Summary of overall view?

Explanation of 2022/2023 excess

More detailed exploration might separately consider:

Projection?

of Actuaries





A practical driver-based approach

Framework and insights

A practical driver-based approach



Institute and Faculty

of Actuaries

Excess mortality is expressed as a percentage uplift to pre-pandemic expectations

Other use-cases



- CMI 2022, males
- 25% weight on 2022
- LTR = 1.5% (with core taper)
- S3PMA base table
- Core parameters elsewhere

...we encourage users of the Model to consider the impact of different choices for Extended and Advanced parameters, including the period smoothing parameter, the initial addition to mortality improvements, and the weight parameters for 2020, 2021



- CMI 2022, males
- 0% weight on 2022
- LTR = 1.5% (with core taper)
- S3PMA base table
- Core parameters elsewhere
- n = 10
- x = ?



What value of x gives the same cohort expectations of life as the data-weighting approach?

0.02

Other use-cases

Age	cEOL 25 pc weight	cEOL 0 pc weight	Initial 2022 excess	Remaining excess at yr 10
50	35.9	36.5	10.0%	5.9%
60	26.2	26.6	5.0%	5.9%
70	17.1	17.5	5.0%	5.3%
80	9.5	9.8	5.0%	4.1%

- 25% weight on 2022 data is equivalent to significant excess remaining at year 10 under a driver-based approach
- At some ages it is equivalent to an increase to the excess
- The result is sensitive to many of the other model assumptions. In particular the length of the LTR convergence periods.



Shape vs strength



- Equivalent expectations of life does not mean equivalent projections
- The shape of a driver-based projection will differ from that of the data-driven approach, because the driver-approach will start from the level of the most-recent datapoint
- The data-driven approach gives 25% to the 2022 data, and will project from a lower initial mortality rate



Practical approaches - conclusions

A driver-based approach can be made simple

- Even a high-level view of how current excess will evolve relative to a pre-pandemic view is useful
- A two-parameter "model" of excess mortality can give useful scenario-based insights into impacts

Alternative methods and viewpoints are useful in times of uncertainty

- Judgement is more important than ever when setting future improvement assumptions
- Being able to approach the problem from different angles is useful

There is no right answer

• All models are wrong, but some are useful!



Acknowledgements

- Working party members:
 - Craig Armstrong, Laura Benton, David Cartmill, Colin Dutkiewicz, Jonathan Finn, Oliver Hampson, Ben Johnson, Hai Luc, Paul Malloy, James Malone, Robert Mellows, Richard Montgomery, Jon Palin, Joanne Wells, Nay Wynn
- Richard Willets for sharing insights as the working party were planning the work
- Thomas Honeywell for checking some of the technical work





Expressions of individual views by members of the Institute and Faculty of Actuaries and its staff are encouraged.

The views expressed in this presentation are those of the presenter.

